|
Oct 2
|
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
|
|
Jul 25
|
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
|
|
May 22
|
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
|
|
Apr 1
|
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
|
|
Jan 9
|
SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
|
|
Dec 5
|
SOHM Announces Business Outlook for 2024
|
|
Aug 24
|
SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor
|
|
Apr 26
|
SOHM Inc. Signed an Exclusive Distribution Agreement with India-based Stallion Laboratories Pvt. Ltd. for Levetiracetam for the Treatment of Epilepsy
|